Assess whether biosimilarity is analytically justified (c9330f)

Situation

Disproportionate reporting signal workbook arrived with a DSMB note on an imbalance that is not yet a signal for RWE evidence-strategy director. That is a Pharma & Life Sciences Pharmacovigilance decision on biosimilarity is analytically justified in an RWE group proposing a post-marketing study instead of a new RCT.

Decision

RWE evidence-strategy director in an RWE group proposing a post-marketing study instead of a new RCT must choose Proceed under protocol / Pause the pathway / Escalate safety review / Hold using disproportionate reporting signal workbook after a DSMB note on an imbalance that is not yet a signal.

Hypotheses to test

• Authorize Proceed under protocol now; disproportionate reporting signal workbook already has the discriminator after a DSMB note on an imbalance that is not yet a signal.
• Keep Pause the pathway in force until disproportionate reporting signal workbook is completed after a DSMB note on an imbalance that is not yet a signal for RWE evidence-strategy director.
• Treat disproportionate reporting signal workbook as Escalate safety review because both readings appear after a DSMB note on an imbalance that is not yet a signal.
• Refuse a Pharma & Life Sciences close: RWE evidence-strategy director does not have the page biosimilarity is analytically justified turns on in disproportionate reporting signal workbook.

Analysis required

• Test a protocol deviation versus a safety signal versus a filing gap on biosimilarity is analytically justified.
• Check whether disproportionate reporting signal workbook supports the labeled claim RWE evidence-strategy director would keep.
• Map FDA-response timing and owner in an RWE group proposing a post-marketing study instead of a new RCT.
• For this Pharma & Life Sciences Pharmacovigilance file, read disproportionate reporting signal workbook against a DSMB note on an imbalance that is not yet a signal and write the one fact that would move biosimilarity is analytically justified for RWE evidence-strategy director.

Recommendation

Choose Proceed under protocol / Pause the pathway / Escalate safety review / Hold on this Pharma & Life Sciences / Pharmacovigilance packet (disproportionate reporting signal workbook after a DSMB note on an imbalance that is not yet a signal). Lead with the Pharma & Life Sciences option disproportionate reporting signal workbook can support after a DSMB note on an imbalance that is not yet a signal, then the two facts that force it, then the Monday action for RWE evidence-strategy director in an RWE group proposing a post-marketing study instead of a new RCT.